WO2003016285A1 - Procedimiento para la preparacion de derivados de 4-(imidazol-1-il)bencenosulfonamida - Google Patents
Procedimiento para la preparacion de derivados de 4-(imidazol-1-il)bencenosulfonamida Download PDFInfo
- Publication number
- WO2003016285A1 WO2003016285A1 PCT/ES2002/000385 ES0200385W WO03016285A1 WO 2003016285 A1 WO2003016285 A1 WO 2003016285A1 ES 0200385 W ES0200385 W ES 0200385W WO 03016285 A1 WO03016285 A1 WO 03016285A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- formula
- compound
- process according
- carried out
- Prior art date
Links
- 0 *c(cc1)ccc1[N+]([O-])=O Chemical compound *c(cc1)ccc1[N+]([O-])=O 0.000 description 5
- KYXDNECMRLFQMZ-UHFFFAOYSA-N COc(ccc(-c([n](cn1)-c(cc2)ccc2S(N)(=O)=O)c1Cl)c1)c1F Chemical compound COc(ccc(-c([n](cn1)-c(cc2)ccc2S(N)(=O)=O)c1Cl)c1)c1F KYXDNECMRLFQMZ-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1S(Cl)(=O)=O)=O Chemical compound [O-][N+](c(cc1)ccc1S(Cl)(=O)=O)=O JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/40—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
Definitions
- the present invention relates to a new process for the preparation of 4- (midazol-1-yl) benzenesulfonamide derivatives, which have application in the therapeutic field.
- R 1 represents aryl or heteroaryl optionally substituted by one or more groups independently selected from halogen, C ⁇ -8 alkyl, C ⁇ -8 haloalkyl, R 2 OC 0-8 alkyl, R 2 SC 0-8 alkyl , cyano, nitro, -NR 2 R 4 , -NR 2 S0 2 R 3 , -SOR 3 , -S0 2 R 3 , -S0 2 NR 2 R 4 or -CONR 2 R 4 ;
- R 2 represents hydrogen, alkyl or C ⁇ -8 arilCo-8 alkyl (where the aryl group may be optionally substituted by one or more groups selected from Ci- ⁇ alkyl, halogen, C1- 8 haloalkyl, cyano, nitro, R 5 OCo - 8 alkyl, R 5 SC 0-8 alkyl, -NR 5 R 6, -NR 5 COR 3, -COR 5 or -COOR 5);
- R 3 represents a C- ⁇ -8 alkyl or C ⁇ -8 haloalkyl group
- R 4 represents hydrogen, C ⁇ - 8 alkyl, arylC ⁇ -8 alkyl (where the aryl group may be optionally substituted by one or more groups selected from C- ⁇ - 8 alkyl, halogen, C ⁇ -8 haloalkyl, cyano, nitro, R 5 OC 0-8 alkyl, R 5 SCo-s alkyl, -NR 5 R 6, -NR 5 COR 3, -COR 5, or -COOR 5), -COR 6 or -COOR 6;
- R 5 represents hydrogen, C- 8 alkyl or benzyl;
- R 6 represents C ⁇ -8 alkyl or C ⁇ -8 haloalkyl;
- aryl represents phenyl or naphthyl;
- Y heteroaryl represents pyridine, pyrazine, pyrimidine or pyridazine, which may be optional
- the method described in WO 00/23426 to prepare these 4- (imidazol-l-yl) benzenesulfonamide derivatives of formula I consists in transforming the corresponding methylsulfoxide derivative -SOCH 3 (that is, a [4- (imidazol-1- yl ) phenyl] methylsulfoxide) in the sulfonamide -S0 2 NH 2 by a method comprising treating said derivative -SOCH 3 with acetic anhydride to give the corresponding acetoxymethylthio derivative (-SCH ⁇ OAc), which is oxidized to give the derivative -SO 2 CH 2 OAC, treatment of this with a base to give the corresponding sodium sulphinate -S0 2 Na, and finally treatment of the derivative -S0 2 Na with hydroxylamino-O-sulfonic acid.
- a method comprising treating said derivative -SOCH 3 with acetic anhydride to give the corresponding acetoxymethylthio derivative
- This synthesis has a high number of stages, so that the overall yield of the process of obtaining the compounds of formula I is low.
- the need to find an alternative procedure to prepare the sulfonamide derivatives of formula I is thus raised.
- This problem is solved with the process object of the present invention, which has a smaller number of stages than that described in the prior art. , provides the compounds of formula I with better yields and can be used on an industrial scale.
- one aspect of the present invention relates to a new process for the preparation of a compound of formula I,
- R, 1 represents aryl or heteroaryl optionally substituted by one or more groups independently selected from halogen, C- 8 alkyl, C-
- R 2 represents hydrogen, C ⁇ . 8 alkyl or arylCo- ⁇ alkyl (where the aryl group may be optionally substituted by one or more groups selected from C ⁇ - 8 alkyl, halogen, C ⁇ - 8 haloalkyl, cyano, nitro, R 5 OC 0-8 alkyl, R 5 SC 0 -8 alkyl, -NR 5 R 6 , -NR 5 COR 3 , -COR 5 or -COOR 5 );
- R 3 represents a group ds alkyl or C ⁇ . 8 haloalkyl
- R 4 represents hydrogen, C ⁇ -8 alkyl, ar ⁇ IC ⁇ -8 alkyl (where the aryl group may be optionally substituted by one or more groups selected from C ⁇ - 8 alkyl, halogen, C ⁇ - 8 haloalkyl, cyano, nitro, R 5 OC 0- 8 alkyl, R 5 SC 0-8 alkyl, -NR 5 R 6, -NR 5 COR 3, -COR 5, or -COOR 5), -COR 6 or -COOR 6;
- R 5 represents hydrogen, C- 8 alkyl or benzyl
- R 6 represents C 1-8 alkyl or C ⁇ - 8 haloalkyl; aryl represents phenyl or naphthyl; and heteroaryl represents pyridine, pyrazine, pyrimidine or pyridazine, which may be optionally fused to a benzene ring; characterized in that it comprises treating a compound of formula II
- R 1 has the meaning defined above for the formula I and Bu 1 represents eti-butyl, with an acid.
- Another aspect of the present invention relates to a process for the preparation of a compound of formula II
- R 1 has the meaning defined above for formula I and Bu 1 represents ethe-butyl, characterized in that it comprises reacting the 4- amino-N-feri-butylbenzenesulfonamide of formula III
- Another aspect of the present invention relates to a process for the preparation of a compound of formula I
- R 1 has the meaning defined above, characterized in that it comprises reacting the 4-amino-N- ⁇ e / f-butylbenzenesulfonamide of formula III
- R 1 and Bu 1 have the meaning defined above, and finally treating said compound of formula II with an acid.
- C ⁇ - 8 alkyl as a group or part of a group, means a linear or branched alkyl group containing from 1 to 8 carbon atoms Examples include among others the groups methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, ⁇ eri-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl.
- a C 0-8 alkyl means that additionally the alkyl group can be absent (ie a covalent bond is present).
- a halogen radical or its abbreviation halo means fluoro, chloro, bromo or iodo.
- a C- 8- haloalkyl group means a group resulting from the substitution of one or more hydrogen atoms of a C- 8- alkyl group with one or more halogen atoms (i.e. fluoro, chloro, bromo or iodo), which can be Same or different.
- halogen atoms i.e. fluoro, chloro, bromo or iodo
- Examples include trifluoromethyl, fluoromethyl, 1-chloroethyl, 2- chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 2-bromoethyl, 2-iodoethyl, pentafluoroethyl, 3-fluoropropyl, 3-chloropropyl, 2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl, heptafluoropropyl, 4-fluorobutyl, nonafluorobutyl, 5- fluoropentyl, 6-fluorohexyl, 7-fluoroheptyl and 8-fluorooctyl.
- An arylC ⁇ -8 alkyl group means a group resulting from the substitution of a hydrogen atom of a C ⁇ -8 alkyl group with an aryl group as defined above, that is phenyl or naphthyl, which may be optionally substituted as described above. .
- Examples include among others the benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1-phenylpropyl, 4-phenylbutyl, 3-phenylbutyl, 2-phenylbutyl, 1-phenylbutyl, 5- phenylpentyl, 6- phenylhexyl, 7-phenylheptyl and 8-phenyloctyl, where the phenyl group may be optionally substituted.
- An arylC 0-8 alkyl group means that it additionally includes an aryl group when the alkyl group is absent (ie, when it is C 0 alkyl).
- the aryl or heteroaryl group may be optionally substituted by one or more, preferably from one to three, groups chosen in each case from a certain group of substituents.
- the substituent (s), when there is more than one, can be in any available position of the aryl or heteroaryl group.
- R 1 represents phenyl or pyridine optionally substituted by one or more groups independently selected from among halogen, C ⁇ . 8 alkyl, C ⁇ - 8 haloalkyl, R 2 OC 0 - 8 alkyl, R 2 SC 0 - 8 alkyl, cyano, nitro, -NR 2 R 4 , -NR 2 S0 2 R 3 , -SOR 3 , -S0 2 R 3 , -S0 2 NR 2 R 4 , or -CONR 2 R 4 .
- R 1 represents phenyl or pyridine optionally substituted with one or more groups independently selected from halogen, C ⁇ -8 alkyl, C ⁇ -8 haloalkyl, R 2 OCo-8 alkyl, R 2 SC 0-8 alkyl,
- R 1 represents phenyl optionally substituted by one or more groups independently selected from halogen and R 2 OC 0 -8 alkyl.
- R 1 represents 3-fluoro-4- methoxyphenyl and the compound of formula I obtained is 4- [4-chloro-5- (3-fluoro-4- methoxyphenyl) imidazol-1-yl] benzenesulfonamide .
- R 1 represents 4-ethoxyphenyl and the compound of formula I obtained is 4- [4-chloro-5- (4-ethoxyphenyl) imidazol-1- yl] benzenesulfonamide.
- the compounds of formula I are obtained from the compounds of formula II by removal of the sulfonamide protecting ethe-butyl group, as shown in the following scheme:
- R 1 has the meaning described above and Bu * represents terf-butyl.
- the elimination of the et-butyl group of a compound of formula II is carried out by treatment with an acid.
- acids useful for such deprotection are trifluoroacetic acid, hydrochloric acid and phosphoric acid.
- the reaction can optionally be carried out within a solvent and at a temperature preferably between room temperature and the boiling point of the solvent, if it is Present.
- hydrochloric acid in aqueous medium and at reflux temperature or trifluoroacetic acid, optionally in dichloromethane, at room temperature can be mentioned.
- the compound of formula I thus obtained can be isolated in a conventional manner and can be purified by the usual methods well known to those skilled in the art, for example by recrystallization from a suitable solvent such as, for example, acetonitrile, methanol, ethanol or isopropanol.
- a suitable solvent such as, for example, acetonitrile, methanol, ethanol or isopropanol.
- R 1 has the meaning described above for the compounds of formula I
- L represents a good leaving group
- Bu * represents ferf-butyl.
- the 4-amino-N-fetf-butylbenzenesulfonamide of formula III is reacted with an aldehyde of formula R 1 -CHO (IV), where R 1 has the meaning described above, to give an imine of formula V
- Said condensation is carried out by refluxing in a suitable solvent such as toluene or benzene and optionally in the presence of acid catalysis such as, for example, p-toluenesulfonic acid, in an azeotropic distillation system.
- the reaction can be carried out using as a reagent of formula VI the tosylmethylisocyanide, a base such as K 2 C 3 and a solvent such as dimethylformamide or methanol-dimethoxyethane mixtures, and heating, preferably at reflux.
- a base such as K 2 C 3
- a solvent such as dimethylformamide or methanol-dimethoxyethane mixtures
- the obtained imidazole (Vil) is chlorinated in position 4 of the ring by treatment with a suitable chlorinating agent and in a suitable solvent, to give a compound of formula II.
- a suitable chlorinating agent we can mention N-chlorosuccinimide and acetonitrile as the preferred solvent.
- the reaction is carried out by heating, preferably at reflux.
- the starting 4-amino-N- ⁇ erf-butylbenzenesulfonamide (III) can be obtained, for example, by either of the two routes indicated in the following scheme:
- Bu * represents eti-butyl and Ac represents acetyl.
- 4-amino-N-te / f-butylbenzenesulfonamide III can be prepared from an N-te / f-butylbenzenesulfonamide of formula IXa or IXb. If starting from the N- ⁇ et ⁇ f-butyl-4-nitrobenzenesulfonamide (IXa), compound III is obtained by reduction of the nitro group by any of the nitro group reduction methods widely described in the literature.
- hydrogen can be used as a reducing agent in the presence of palladium on carbon and within a suitable solvent such as ethanol or methanol, or SnCI 2 within a suitable solvent such as ethanol.
- compound III is obtained by deprotection of the amine, for example in basic medium, using a base such as KOH in a suitable solvent , for example water or water-methanol mixtures.
- N-tetf-butylbenzenesulfonamides of formulas IXa and IXb can be obtained from the corresponding sulfonyl chloride (Villa and Vlllb, respectively) by reaction with te / Y-butylamine within a suitable solvent such as for example tetrahydrofuran, dimethoxyethane or ethyl acetate, at a temperature between room temperature and the boiling temperature of the solvent.
- a suitable solvent such as for example tetrahydrofuran, dimethoxyethane or ethyl acetate
- the compounds of formulas VI, Villa and Vlllb are commercial.
- the aldehydes of formula IV, depending on their structure, are commercial or can be obtained by methods described in the literature, for example as described in WO 00/23426.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003521211A JP4309262B2 (ja) | 2001-08-07 | 2002-08-01 | 4−(イミダゾール−1−イル)ベンゼンスルホンアミド誘導体の製造方法 |
EP02794802A EP1424329B1 (en) | 2001-08-07 | 2002-08-01 | Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives |
DE60226879T DE60226879D1 (de) | 2001-08-07 | 2002-08-01 | Verfahren zur herstellung von 4-(imidazol-1-yl)benzolsulfonamidderivaten |
BRPI0211749A BRPI0211749B8 (pt) | 2001-08-07 | 2002-08-01 | processo para a preparação de derivados de 4-(imidazol-1- il)benzenossulfonamida |
MXPA04001147A MXPA04001147A (es) | 2001-08-07 | 2002-08-01 | Procedimiento para la preparacion de derivados de 4-(imidazol-1-il)bencenosulfonamida. |
US10/485,950 US7351836B2 (en) | 2001-08-07 | 2002-08-01 | Method of preparing 4-(imidazol-1-yl)benzenesulphonamide derivatives |
KR1020047001749A KR100888905B1 (ko) | 2001-08-07 | 2002-08-01 | 4-(이미다졸-1-일)벤젠술폰아미드 유도체의 제조 방법 |
DK02794802T DK1424329T3 (da) | 2001-08-07 | 2002-08-01 | Fremgangsmåde til fremstillingen af 4-(imidazol-1-yl)benzensulfonamid |
CA2456531A CA2456531C (en) | 2001-08-07 | 2002-08-01 | Process for the preparation of 4-(imidazole-1-yl)benzenesulfonamide derivatives |
NO20040981A NO326162B1 (no) | 2001-08-07 | 2004-03-05 | Fremgangsmate for fremstilling av 4-(imidazol-1-yl)benzensulfonamidderivater. |
HK04109044A HK1066214A1 (en) | 2001-08-07 | 2004-11-17 | Process for the preparation of 4-(imidazol-1-yl) benzenesulfonamide derivatives |
US12/060,574 US8476456B2 (en) | 2001-08-07 | 2008-04-01 | Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP0101853 | 2001-08-07 | ||
ES200101853A ES2184633B1 (es) | 2001-08-07 | 2001-08-07 | Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida. |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10485950 A-371-Of-International | 2002-08-01 | ||
US12/060,574 Division US8476456B2 (en) | 2001-08-07 | 2008-04-01 | Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003016285A1 true WO2003016285A1 (es) | 2003-02-27 |
WO2003016285A8 WO2003016285A8 (es) | 2003-08-28 |
Family
ID=8498662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2002/000385 WO2003016285A1 (es) | 2001-08-07 | 2002-08-01 | Procedimiento para la preparacion de derivados de 4-(imidazol-1-il)bencenosulfonamida |
Country Status (17)
Country | Link |
---|---|
US (2) | US7351836B2 (es) |
EP (1) | EP1424329B1 (es) |
JP (1) | JP4309262B2 (es) |
KR (1) | KR100888905B1 (es) |
AR (2) | AR037231A1 (es) |
AT (1) | ATE396976T1 (es) |
BR (1) | BRPI0211749B8 (es) |
CA (1) | CA2456531C (es) |
CY (1) | CY1108861T1 (es) |
DE (1) | DE60226879D1 (es) |
DK (1) | DK1424329T3 (es) |
ES (2) | ES2184633B1 (es) |
HK (1) | HK1066214A1 (es) |
MX (1) | MXPA04001147A (es) |
NO (1) | NO326162B1 (es) |
PT (1) | PT1424329E (es) |
WO (1) | WO2003016285A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2015DN00202A (es) | 2012-07-12 | 2015-06-12 | Chiesi Farma Spa | |
WO2022269384A1 (en) * | 2021-06-24 | 2022-12-29 | Ami Organics Ltd. | A process for the direct synthesis of fedratinib intermediate |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064415A1 (en) * | 1998-06-11 | 1999-12-16 | Pfizer Pharmaceuticals Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
WO2000023426A1 (es) * | 1998-10-16 | 2000-04-27 | J. Uriach & Cia, S.A. | Nuevos imidazoles con actividad antiinflamatoria |
WO2001070704A1 (es) * | 2000-03-23 | 2001-09-27 | J. Uriach & Cia S.A. | Nuevos derivados de imidazol con actividad antiinflamatoria |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69935913T2 (de) * | 1998-07-02 | 2008-01-10 | Cryptography Research Inc., San Francisco | Leckresistente aktualisierung eines indexierten kryptographischen schlüssels |
-
2001
- 2001-08-07 ES ES200101853A patent/ES2184633B1/es not_active Expired - Fee Related
-
2002
- 2002-08-01 CA CA2456531A patent/CA2456531C/en not_active Expired - Lifetime
- 2002-08-01 MX MXPA04001147A patent/MXPA04001147A/es active IP Right Grant
- 2002-08-01 JP JP2003521211A patent/JP4309262B2/ja not_active Expired - Fee Related
- 2002-08-01 DE DE60226879T patent/DE60226879D1/de not_active Expired - Lifetime
- 2002-08-01 AT AT02794802T patent/ATE396976T1/de active
- 2002-08-01 US US10/485,950 patent/US7351836B2/en not_active Expired - Fee Related
- 2002-08-01 EP EP02794802A patent/EP1424329B1/en not_active Expired - Lifetime
- 2002-08-01 ES ES02794802T patent/ES2307817T3/es not_active Expired - Lifetime
- 2002-08-01 WO PCT/ES2002/000385 patent/WO2003016285A1/es active IP Right Grant
- 2002-08-01 BR BRPI0211749A patent/BRPI0211749B8/pt not_active IP Right Cessation
- 2002-08-01 DK DK02794802T patent/DK1424329T3/da active
- 2002-08-01 PT PT02794802T patent/PT1424329E/pt unknown
- 2002-08-01 KR KR1020047001749A patent/KR100888905B1/ko not_active IP Right Cessation
- 2002-08-06 AR ARP020102972A patent/AR037231A1/es not_active Application Discontinuation
-
2004
- 2004-03-05 NO NO20040981A patent/NO326162B1/no not_active IP Right Cessation
- 2004-11-17 HK HK04109044A patent/HK1066214A1/xx not_active IP Right Cessation
-
2008
- 2008-04-01 US US12/060,574 patent/US8476456B2/en not_active Expired - Fee Related
- 2008-08-21 CY CY20081100892T patent/CY1108861T1/el unknown
-
2012
- 2012-04-25 AR ARP120101436A patent/AR086065A2/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064415A1 (en) * | 1998-06-11 | 1999-12-16 | Pfizer Pharmaceuticals Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
WO2000023426A1 (es) * | 1998-10-16 | 2000-04-27 | J. Uriach & Cia, S.A. | Nuevos imidazoles con actividad antiinflamatoria |
WO2001070704A1 (es) * | 2000-03-23 | 2001-09-27 | J. Uriach & Cia S.A. | Nuevos derivados de imidazol con actividad antiinflamatoria |
Also Published As
Publication number | Publication date |
---|---|
AR086065A2 (es) | 2013-11-13 |
KR20040020079A (ko) | 2004-03-06 |
ES2184633A1 (es) | 2003-04-01 |
US8476456B2 (en) | 2013-07-02 |
MXPA04001147A (es) | 2004-07-08 |
AR037231A1 (es) | 2004-11-03 |
ES2307817T3 (es) | 2008-12-01 |
JP2005502659A (ja) | 2005-01-27 |
CY1108861T1 (el) | 2014-08-13 |
NO326162B1 (no) | 2008-10-13 |
KR100888905B1 (ko) | 2009-03-16 |
CA2456531A1 (en) | 2003-02-27 |
BR0211749B1 (pt) | 2013-09-10 |
DE60226879D1 (de) | 2008-07-10 |
WO2003016285A8 (es) | 2003-08-28 |
ATE396976T1 (de) | 2008-06-15 |
EP1424329A1 (en) | 2004-06-02 |
EP1424329B1 (en) | 2008-05-28 |
US7351836B2 (en) | 2008-04-01 |
BR0211749A (pt) | 2004-10-13 |
US20090012307A1 (en) | 2009-01-08 |
HK1066214A1 (en) | 2005-03-18 |
NO20040981L (no) | 2004-03-05 |
ES2184633B1 (es) | 2004-08-01 |
BRPI0211749B8 (pt) | 2021-05-25 |
DK1424329T3 (da) | 2008-09-29 |
CA2456531C (en) | 2010-12-14 |
JP4309262B2 (ja) | 2009-08-05 |
PT1424329E (pt) | 2008-08-06 |
US20040242872A1 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016018581B1 (pt) | Processo para a fabricação de derivados de sulfamida pirimidina | |
RU2174978C2 (ru) | Способ получения производных пиримидина, промежуточные продукты и способ их получения | |
ES2307817T3 (es) | Procedimiento para la preparacion de derivados de 4-(imidazol-1-il)bencenosulfanomida. | |
KR20120071339A (ko) | 벤다무스틴 알킬 에스테르, 벤다무스틴, 및 이의 유도체의 제조 방법 | |
SU622399A3 (ru) | Способ получени солей арилсульфониламидоалкиламинов | |
JP2021511325A (ja) | スルフェントラゾンの合成のための方法 | |
JP4000433B2 (ja) | ピラゾロ〔1,5−a〕ピリミジン誘導体 | |
ES2227807T3 (es) | Proceso para la fabricacion de cloruro de arilsulfonilo. | |
KR20110133913A (ko) | 신규한 설포닐옥시메틸포스포네이트 유도체 및 이를 이용한 다이아이소프로필 ((1-(트리틸옥시메틸)-사이클로프로필)옥시)메틸 포스포네이트의 제조방법 | |
JP3067845B2 (ja) | N−アルキルスルホニルアミノスルホニル尿素の製造方法 | |
JPS6355512B2 (es) | ||
JP3127505B2 (ja) | ピラゾロピリジン誘導体の製造法 | |
ES2441545T3 (es) | Método para producir un compuesto de 2,3-dihidropiridazina | |
UA59373C2 (uk) | Феноксифенілсульфонілгалоїд та спосіб одержання похідної феноксифенілсульфонілу | |
KR20030085788A (ko) | 피리딘 유도체, 그의 제조방법, 및 제초제 중간체로서의용도 | |
JP2533690B2 (ja) | スルホンアミド誘導体 | |
JPS595586B2 (ja) | ピロ−ル誘導体の製造方法 | |
JPS59157044A (ja) | 隣位のポリカルボニル化合物の製法 | |
KR100701420B1 (ko) | 비페닐테트라졸 유도체의 제조방법 | |
CA3227445A1 (en) | Production method for synthetic intermediate of monocyclic pyridine derivative | |
JPS6149303B2 (es) | ||
JP2000072741A (ja) | ハロゲン化合物の製造方法 | |
JPH04103589A (ja) | 3′―アルキルまたはアリールシリルオキシベンゾキサジノリファマイシン誘導体 | |
JPH0249771A (ja) | ピラゾール‐5‐カルボキサミド類の製造方法 | |
JPH01226862A (ja) | N,n−ジアルキルヒドラジン類の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 09/2003 UNDER (72, 75) REPLACE ""GONZALES GONZALES, CONCEPCION [-/-]"" BY ""GONZALES GONZALES, CONCEPCION [ES/ES]"" |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/001147 Country of ref document: MX Ref document number: 1020047001749 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2456531 Country of ref document: CA Ref document number: 2002794802 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003521211 Country of ref document: JP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 09/2003 UNDER (71) THE NAME SHOULD READ "J. URIACH & CIA. S.A."; UNDER (72, 75) THE NAME SHOULD READ "GONZALEZ GONZALEZ, CONCEPCION" |
|
WWP | Wipo information: published in national office |
Ref document number: 2002794802 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10485950 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002794802 Country of ref document: EP |